11β-HSD1 inhibition ameliorates diabetes-induced cardiomyocyte hypertrophy and cardiac fibrosis through modulation of EGFR activity

11β-HSD1 has been recognized as a potential therapeutic target for type 2 diabetes. Recent studies have shown that hyperglycemia leads to activation of 11β-HSD1, increasing the intracellular glucocorticoid levels. Excess glucocorticoids may lead to the clinical manifestations of cardiac injury. Ther...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Zou, Chunpeng, Li, Weixin, Pan, Yong, Khan, Zia A., Li, Jieli, Wu, Xixi, Wang, Yi, Deng, Liancheng, Liang, Guang, Zhao, Yunjie
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5707098/
https://ncbi.nlm.nih.gov/pubmed/29221204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22015
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars